Introduction:Drug addiction is considered one of the serious problems. Clinical profile of drug dependence is continuously changing taking new shape, new drugs and routes. From 2004, illicit drug manufacturers began to produce herbal smoking substances under a wide range of brand names. Recently over the past two to three years, the drug abuse market in Egypt was invaded by a new herbal preparation, called "Strox" that gained favor among abusers and rapidly spread. Aim of Study: to evaluate the strox toxicity cases including; the presenting symptoms and signs, the lines of treatment and highlight the outcomes secondary to strox exposure, also correlate the presenting clinical pictures with strox structure. Methodology: A cross sectional observational study carried out at Poison Control Center Ain Shams University (PCC-ASU). The study included all strox intoxicated patients presented to PCC-ASU from the first of Jan. 2017 to the end of Jan. 2018, and the obtained seized Strox packages screened by Gas Chromatography (GC). Results: there were 84 patients. The mean age was 25±9.8 year. The median of delay time was 2-4 hours. Disturbed conscious level observed in 45% of patients, chest pain (37%), shortness of breathing (32%). Hypoxemia was evident in 65% of cases, associated with Hypercapnia and respiratory acidosis in 50 % of cases. No observed changes regarding serum electrolytes, renal function or random blood sugar. ST segment depression and T wave inversion were reported in 6% of cases. All patients were admitted and received supportive treatment. Gas chromatographic analysis of some Strox packages revealed the presence of xylene, methylene dioxy methamphetamine, and trihexyphenidyl. Conclusion: Patients with Strox smoking presented with transient coma, hallucinations, impaired ventilation, and chest pain. The displayed picture was attributed to a mixture of xylene, MDMA, and the central anti-cholinergic trihexiphenidyl. The picture was confirmed by gas chromatography analysis of seized strox package.
Background: Paracetamol toxicity is a common toxicity that can result in severe hepatic damage, which can progress to liver failure. Traditional liver markers, have limitations in early detection. Aim: The present work aims to evaluate the efficacy of miRNA-122 serum level in detecting the degree of liver affection in the early phases of acute paracetamol toxicity. Methods: This prospective study was conducted by collecting demographic, clinical data and blood samples from 35 acute single paracetamol toxicity patients admitted to the Poison Control Centre of Ain Shams University. Liver function tests, serum miRNA-122 expression and paracetamol level were measured on admission, at 24 and 48 hours. 35 controls matched to age and gender, were used as a reference to the lab results. Results: The studied patients with acute paracetamol toxicity were 10 males (28.6%) and 25 females (71.4%). Mean age was 25.3 years ± 6.7. The levels of miRNA-122 on admission were statistically significantly higher in patients than in controls. The levels of ALT and INR increased statistically significantly over time, whereas paracetamol and miRNA-122 decreased statistically significantly over time. MiRNA-122 expression showed a strong positive correlation with the amount of paracetamol consumed, ALT levels (p < 0.000), and length of hospital stay, and a moderate correlation with INR (p = 0.010). Conclusions: This study provides evidence supporting the potential role of miRNA-122 as a biomarker for early detection of the degree of liver injury in acute paracetamol toxicity patients. MiRNA-122 demonstrated superior sensitivity and specificity compared to traditional liver markers.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.